NCT05029102招募中2 期
TAS-102 Combined With Anlotinib in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments (THALIA): a Prospective Single-arm Phase II Study
Zhejiang University1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2021年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Progression Free Survival
研究概览
简要总结
To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years, ≤75 years
- •Histologically confirmed gastric cancer with distant metastasis
- •Progression on ≥ 2 lines of prior standard chemotherapy
- •Patients can swallow pills normally
- •Expected overall survival ≥6 months
- •Blood routine: no blood transfusion or blood products usage within 14 days, G-CSF or other hematopoietic stimulator was not used. WBC counts > 3000/µl，Absolute neutrophil count (ANC) ≥ 1500 cells/µl，Platelet count ≥ 100,000/µl，Hemoglobin ≥ 9.0 g/dL.
- •AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum bilirubin ≤ 1.5 x ULN，creatinine<ULN
- •Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN
- •Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment;
- •Informed consent has been signed.
排除标准
- •Active bleeding within 3 months; Occurrence of arterial/venous thrombosis within 6 months; Hereditary or acquired bleeding (e.g., clotting dysfunction) or thrombotic tendencies; Full dose oral or injectable anticoagulants or thrombolytic drugs for therapeutic purposes are currently being used or have been used recently (10 days prior to the commencement of study treatment); Surgery (except for biopsy) was performed within 4 weeks prior to the study or the surgical incision was not fully healed; Aspirin (> 325 mg/ day) or dipyridamole, ticlopidine, clopidogrel, and silotazole are currently being used or have recently been used (10 days prior to the study).
- •Certain or suspected brain metastases.
- •Patients who have received prior therapy of any study drug;
- •Serious uncontrolled systemic diseases, such as severe active infections;
- •A person is known to be infected with the immunodeficiency virus (HIV) or known to be HIV-positive;
- •Patients have suffered from other malignancies in the past 5 years except cervical carcinoma in situ or basal cell carcinoma of the skin
- •Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA >500 IU/mL) or active HCV carriers with HCV RNA can be detected. Remarks: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA < 500 IU/mL) may be enrolled
- •Anti-infective therapy was not discontinued 14 days before the study;
- •A prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia, and symptomatic interstitial lung disease or the presence of active pneumonia on a chest CT scan within 4 weeks prior to the study.
- •Patients have a history of intestinal obstruction within six months. Patients with incomplete obstruction syndrome of ileus at the time of initial diagnosis may be enrolled in the study if they have received definitive (surgical) treatment to resolve the symptoms, as assessed by the investigator.
- •Patients have high blood pressure that cannot be well controlled by antihypertensive medication (systolic ≥140 mmHg or diastolic ≥90 mmHg)
- •Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein >1.0g;
- •Known to be allergic to any study drug;
- •Patients have participated in other drug clinical studies within 4 weeks before enrollment;
- •Lactating women
- •According to the judgment of the researcher, the patient may have other factors that may affect the results of the study or cause the study to be terminated, such as alcohol abuse, drug abuse, other serious diseases (including mental diseases) requiring combined treatment. Patients have severe laboratory abnormalities, which will affect the safety of the patient.
研究组 & 干预措施
TAS-102 and Anlotinib
Experimental
TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
干预措施: TAS 102 (Drug)
TAS-102 and Anlotinib
Experimental
TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
干预措施: Anlotinib (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: 4 months
The time elapsed between treatment initiation and tumor progression
次要结局
- Overall Response Rate(2 months)
- Overall Survival(9 months)
研究者
Weijia Fang, MD
Director of Medical Oncology
Zhejiang University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric CancerGastric Cancer Adenocarcinoma MetastaticNCT06711471LIN YANG31
Unknown
2 期
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05266820Fujian Cancer Hospital120
撤回
2 期
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)Gastrointestinal Stromal TumorsNCT02342600Sarcoma Alliance for Research through Collaboration
Unknown
不适用
Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric CancerAdvanced Gastric CancerNCT03255811DongMa40
已完成
2 期
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerStomach NeoplasmsNeoplasms MetastasisERBB2 Gene AmplificationNCT02004769Sun Yat-sen University67